Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Masaki Miyazawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0341-1123; OpenAlex author ID A5083631538. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 7

  1. Pilot validation of a whole-blood mRNA expression-based diagnostic system for early-stage pancreatic ductal adenocarcinoma: a single-center case-control diagno… Co-author DOI 10.1038/s41598-026-58684-8↗
  2. Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44276-024-00116-z↗
  3. Metachronous Pancreatic Cancer with Pancreaticobiliary Maljunction Diagnosed Five Years after Cholecystectomy for Gallbladder Cancer, in Which Follow-up Imagin… Co-author DOI 10.2169/internalmedicine.4581-24↗
  4. miR-4653-3p overexpression is associated with a poor prognosis of pancreatic ductal adenocarcinoma via HIPK2 downregulation. First author DOI 10.1038/s41598-022-22950-2↗
  5. Efficacy of a novel self-expandable metal stent with dumbbell-shaped flare ends for distal biliary obstruction due to unresectable pancreatic cancer. Co-author DOI 10.1038/s41598-022-25186-2↗
  6. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. First author DOI 10.1111/cas.13944↗
  7. Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13396↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Yamashita · 5 shared papers, 2019–2026 · strength 0.90
  2. Akihiro Seki · 3 shared papers, 2025–2026 · strength 0.69
  3. Takeshi Terashima · 2 shared papers, 2025 · strength 0.39
  4. Shuichi Kaneko · 3 shared papers, 2017–2022 · strength 0.27
  5. Yoshio Sakai · 3 shared papers, 2017–2022 · strength 0.27
  6. Motoharu Seiki · 1 shared paper, 2025 · strength 0.20
  7. Naohiko Koshikawa · 1 shared paper, 2025 · strength 0.20
  8. Makoto Ueno · 1 shared paper, 2025 · strength 0.20
  9. Aya Kawanishi · 1 shared paper, 2022 · strength 0.16
  10. Toshio Nakagohri · 1 shared paper, 2022 · strength 0.16
  11. Tsubasa Saika · 1 shared paper, 2022 · strength 0.16
  12. Kenichi Hirabayashi · 1 shared paper, 2022 · strength 0.16
  13. Naoya Nakamura · 1 shared paper, 2022 · strength 0.16
  14. Masashi Morimachi · 1 shared paper, 2022 · strength 0.16
  15. Takuya Komura · 2 shared papers, 2017–2019 · strength 0.14
  16. Tuyen Thuy Bich Ho · 1 shared paper, 2019 · strength 0.08
  17. Alessandro Nasti · 1 shared paper, 2019 · strength 0.08
  18. Tetsuo Ohta · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.